Welcome to our dedicated page for Charlottes Web news (Ticker: CWBHF), a resource for investors and traders seeking the latest updates and insights on Charlottes Web stock.
Charlotte's Web Holdings, Inc. (CWBHF) generates frequent news as a botanical wellness innovation company and market leader in hemp extract wellness and hemp-derived CBD wellness products. Headquartered in Louisville, Colorado and listed on the Toronto Stock Exchange under the symbol CWEB, the company issues regular updates on product launches, operational developments, financial results, and regulatory engagement.
News about Charlotte's Web often highlights new product introductions across CBD oil tinctures, CBD gummies, CBN and CBG gummies, hemp-derived THC microdose gummies, Brightside hemp-derived THC gummies, functional mushroom gummies, and CBD pet products for dogs. Recent announcements include the launch of Quiet Sleep Mushroom Gummies, a melatonin-free and cannabinoid-free sleep support product, and Knockout hemp THC sleep gummies under the Brightside brand, which use a rapid-onset delivery technology.
Investors and followers can also expect coverage of the company's financial performance through quarterly earnings releases, where Charlotte's Web discusses revenue trends, cost structure initiatives, and manufacturing internalization, particularly for gummy production. Additional news items describe the formation of a Scientific Advisory Board, expansion of the medical channel strategy, and participation in a Medicare and Medicaid Innovation pilot program to provide CBD options for senior oncology patients.
Regulatory and policy developments are another recurring theme. Charlotte's Web reports on federal and state-level hemp and CBD regulation, its involvement in industry coalitions such as ONE HEMP, and its perspective on proposed THC limits for hemp-derived products. Updates related to DeFloria, Inc., the Phase 2 clinical-stage botanical pharmaceutical company formed with AJNA BioSciences PBC and supported by a subsidiary of British American Tobacco plc, also appear in the news, including progress on AJA001 oral solution for irritability associated with autism spectrum disorder.
For investors, analysts, and consumers, the Charlotte's Web news feed provides ongoing insight into the company's product pipeline, strategic priorities, regulatory environment, and role in the evolving hemp and botanical wellness market.
Charlotte's Web (BTI) reported Q4 2025 and full-year results and disclosed a material strategic transaction with British American Tobacco (BAT) and participation in the CMMI Medicare pilot.
Highlights: FY revenue $49.9M, FY gross profit $21.7M (43.5%), Q4 revenue $13.3M, Q4 net loss $11.5M. BAT transaction would convert C$75.3M debenture, add US$10M equity, and leave BAT with ~40% ownership pending approvals.
Charlotte's Web (OTCQB: CWBHF / TSX: CWEB) announced a transaction with BAT (British American Tobacco) to convert C$75.3M principal plus C$14.2M accrued interest into equity at C$0.94 and for BAT to invest an additional US$10M via private placement.
The deal issues ~110M shares to BAT, eliminates ~US$65M debt, stops future interest accrual, and would leave BAT with ~40.8% ownership subject to shareholder and TSX approvals.
Charlotte's Web (OTC: CWBHF) will release its 2025 fourth quarter and full year financial results before market open on March 31, 2026. A conference call to review results is scheduled the same day at 11:00 A.M. ET, with multiple participation options and a replay available through April 7, 2026.
The company said the call will include a live webcast and an extended replay on the investor relations website; registration and dial‑in details are provided for investors and analysts.
Charlotte's Web (OTCQB: CWBHF) welcomed new CMS guidance announced March 2026 that creates structured access to eligible full‑spectrum hemp products through CMS Innovation Center models. CMS's BEI guidance defines eligible orally administered hemp products as containing up to 3 mg THC per serving, enabling non‑intoxicating full‑spectrum CBD options in clinical conversations.
The company says the framework supports patient‑provider discussions, emphasizes consumer safety and product quality, and aligns with Charlotte's Web's mission to advance safe, science‑backed hemp wellness products.
Charlotte's Web (OTC: CWBHF) praised Representative Morgan Griffith for leading the introduction of the HEMP Act, a federal hemp bill described as establishing FDA oversight, manufacturing standards, and consumer safety requirements while preserving lawful access to compliant CBD products. The company said the framework aims to target unsafe and illicit products while protecting responsible, lawfully sold hemp-derived cannabinoids used by patients, veterans, and other consumers.
Charlotte's Web also thanked patient advocates and Coalition for Access Now for uniting stakeholders behind a science-based hemp marketplace.
DeFloria (OTCQB:CWBHF) says a Presidential Executive Order reclassifying cannabis to Schedule III accelerates its FDA botanical drug program for autism-related irritability. DeFloria reports a cleared botanical IND, a Study May Proceed letter, a completed Phase 1 PK/PD trial showing safety and tolerability, and FDA authorization to start a Phase 2 program for AJA001 oral solution. The company positions these milestones and standardized pharmaceutical-grade formulation as catalysts for research funding, academic trials, institutional investment, and pharma partnerships after rescheduling on Dec 19, 2025.
Charlotte's Web (OTCQB: CWBHF) will serve as a CBD provider in a landmark CMMI Medicare and Medicaid pilot announced Dec 18, 2025, enabling reimbursement for science-backed CBD for senior oncology patients.
The company plans to offer selected products early 2026 via a secure online healthcare portal that combines eCommerce with advanced data security. The pilot pairs Realm of Caring for patient support and the company's Scientific Advisory Board for clinical guidance, and targets improved affordability for seniors within a population of 67 million Medicare beneficiaries.
ONE HEMP (CWBHF) warns that language in the Agriculture, Rural Development, and FDA Appropriations Act would effectively ban many full-spectrum CBD products by imposing a 0.4 mg total THC per container limit, which the group calls unscientific and harmful to consumer access. ONE HEMP cites peer-reviewed research (Dr. Ryan Vandrey) and industry experts (Dr. Marcel Bonn-Miller) to argue that oral THC up to 2.8 mg shows no subjective impairment and that trace THC supports a full-spectrum "entourage effect."
The bill includes a one-year implementation window; House and Senate lawmakers are preparing parallel legislative responses to establish manufacturing, labeling, synthetic cannabinoid prohibitions, and youth safeguards. ONE HEMP is mobilizing stakeholders to seek balanced, science-based regulation that preserves consumer access and public health.
Charlotte's Web (OTC:CWBHF) reported Q3 2025 results on Nov 12, 2025: consolidated revenue of $11.5M (down 8.6% YoY), gross profit of $4.5M (38.9% margin), and net loss of $5.8M or $(0.04) per share. Adjusted EBITDA improved to $(2.1)M from $(3.9)M a year ago.
Operational highlights include full internalization of Brightside gummy manufacturing, a Scientific Advisory Board launch, a B2B channel restructuring with a $0.5M chargeback reserve, and FDA clearance for DeFloria Phase 2 IND for ASD irritability. Cash was $9.8M and total assets $81.6M as of Sept 30, 2025.
Charlotte's Web (OTCQB: CWBHF) announced the appointment of M. Borgia Walker to its Board of Directors, effective November 1, 2025. Walker brings ~30 years of leadership in transformation, finance, audit, compliance, HR and M&A from global consumer goods and financial services.
She currently serves as Chief People Officer at Reynolds American, led a multi-year transformation as VP of Strategic Projects (2017–2023), is a CPA, and holds a BS in Accountancy plus an MBA in Finance. Walker replaces Jonathan Atwood and increases the board to six directors.